Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

Could Provide Competition For SGLT2 Inhibitors

 
• By Kevin Grogan
  
Bayer Pharma AG, Administration and laboratory buildings of Bayer HealthCare Pharmaceuticals in Berlin-Wedding on June 14, 2017, Germany - Image
The German major has high hopes for finerenone • Source: Shutterstock

More from Genitourinary

More from Therapy Areas